The European ankylosing spondylitis infliximab cohort (EASIC): A European multicentre study of long-term outcomes in patients with ankylosing spondylitis treated with infliximab

Clinical and Experimental Rheumatology

Volumn 29, Issue 4, 2011, Pages 672-680

  Heldmann, Frank ^a   Brandt, Jan ^b   van der Horst Bruinsma, Irene E ^c   Landewe, Robert ^d   Sieper, Joachim ^b   Burmester, Gerd Rüdiger ^b   van den Bosch, Filip ^e   de Vlam, Kurt ^f   Geusens, Piet ^g   Gaston, Hill ^h   Schewe, Stefan ⁱ   Appelboom, Thierry ^j   Emery, Paul ^k   Dougados, Maxime ^l   Leirisalo Repo, Marjatta ^m   Breban, Maxime ⁿ   Listing, Joachim ^o   Braun, Jürgen ^a  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g HASSELT UNIVERSITY   (Belgium)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j ERASME HOSPITAL   (Belgium)

^k UNIVERSITY OF LEEDS   (United Kingdom)

^l Hopital Erasme Brussels ^*  (France)

^m HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁿ HÔPITAL AMBROISE PARÉ   (France)

^o DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

more..

Author keywords

Ankylosing spondylitis; Anti TNF; Infliximab

Indexed keywords

INFLIXIMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; EAR INFECTION; EUROPE; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; INFECTION; INFUSION RELATED REACTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PREGNANCY; PRIORITY JOURNAL; RELAPSE; REMISSION; SIDE EFFECT; SKIN INFECTION; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT INFECTION; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; PATIENT; RECURRENT DISEASE; TIME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; DRUG HYPERSENSITIVITY; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PREGNANCY; RECURRENCE; REMISSION INDUCTION; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME;

EID: 80055097919     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. BRAUN J, VAN DER HEIJDE D: Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin Invest Drugs 2003; 12: 1097-109.
2. BRAUN J, BOLLOW M, REMLINGER G et al.: Prevalence of spondyloarthropathies in HLA B27 positive and negative blood donors. Arthritis Rheum 1998; 41: 58-67.
3. SIEPER J, BRAUN J, RUDWALEIT M, BOONEN A, ZINK A: Ankylosing spondylitis: an overview. Ann Rheum Dis 2002; 61 (Suppl. 3): iii8-18.
4. ZOCHLING J, VAN DER HEIJDE D, BURGOSTable VARGAS R et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-52.
5. BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
6. BRANDT J, HAIBEL H, CORNELY D et al.: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346-52.
7. BRANDT J, HAIBEL H, SIEPER J, REDDIG J, BRAUN J: Infliximab treatment of severe ankylosing spondylitis: one-year follow-up (letter). Arthritis Rheum 2001; 45: 2936-7.
8. BREBAN M, VIGNON E, CLAUDEPIERRE P et al.: Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology 2002; 41: 1280-5.
9. BRAUN J, BRANDT J, LISTING J et al.: Longterm efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open-label, observational extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48: 2224-33.
10. VAN DER HEIJDE D, DIJKMANS B, GEUSENS P et al.; AND THE ANKYLOSING SPONDYLITIS STUDY FOR THE EVALUATION OF RECOMBINANT INFLIXIMAB THERAPY STUDY GROUP: Efficacy and safety of infliximab in patients with Ankylosing Spondylitis. Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582-91.
11. BRAUN J, DEODHAR A, DIJKMANS B et al.; ANKYLOSING SPONDYLITS STUDY FOR THE EVALUATION OF RECOMBINANT INFLIXIMAB THERAPY STUDY GROUP: Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008; 59: 1270-8.
12. BRAUN J, LANDEWÉ R, HERMANN KG et al.; ASSERT STUDY GROUP: Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006; 54: 1646-52.
13. BARALIAKOS X, LISTING J, BRANDT J et al.: Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the TNF-alpha antibody infliximab. Rheumatology 2007; 46: 1450-3.
14. BARALIAKOS X, LISTING J, RUDWALEIT M, BRANDT J, SIEPER J, BRAUN J: Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005; 64: 1462-6.
15. BRAUN J, KALDEN JR: Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27 (Suppl. 55): S164-7.
16. VAN DER HEIJDE D, LANDEWÉ R, EINSTEIN S et al.: Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58: 1324-31.
17. VAN DER HEIJDE D, LANDEWÉ R, BARALIAKOS X Et Al.: Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group: Arthritis Rheum 2008; 58: 3063-70.
18. VAN DER HEIJDE D, LANDEWÉ R, MAKSYMOVYCH W et al.: Adalimumab (Humira) Therapy for Ankylosing Spondylitis over 2 years does not demonstrate inhibition of radiographic progression compared with a historical control group. Abstract 670; ACR 2008.
19. BRAUN J, BARALIAKOS X, LISTING J et al.: Persistent clinical efficacy and safety of antitumour necrosis factor a therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008; 67: 340-5.
20. BOONEN A, MAU W: The economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27 (Suppl. 55): S112-7.
21. FRANKE LC, AMENT AJ, VAN DE LAAR MA, BOONEN A, SEVERENS JL: Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27 (Suppl. 55): S118-23.
22. VAN DER HEIJDE D, DOUGADOS M, DAVIS J et al.: ASsessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 2005; 52: 386-94.
23. GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
24. CALIN A, GARRETT S, WHITELOCK H et al.: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5.
25. JENKINSON TR, MALLORIE PA, WHITELOCK HC, KENNEDY LG, GARRETT SL, CALIN A: Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994; 21: 1694-8.
26. BREBAN M, RAVAUD P, CLAUDEPIERRE P et al.: Maintenance of infliximab treatmentin ankylosing spondylitis. Results of a oneyear randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008; 58: 88-97.
27. BARALIAKOS X, LISTING J, RUDWALEIT M et al.: Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 2007; 34: 510-5.
28. BARALIAKOS X, LISTING J, BRANDT J et al.: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005; 7: R439-44.
29. DAVIS JC JR, VAN DER HEIJDE D, BRAUN J et al.: Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008; 67: 346-52.
30. DIJKMANS B, EMERY P, HAKALA M et al.: Etanercept in the long-term treatment of patients with ankylosing spondylitis. J Rheumatol 2009; 36: 1256-64.
31. DAVIS JC, VAN DER HEIJDE DM, BRAUN J et al.: Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005; 64: 1557-62.
32. NIKAS SN, ALAMANOS Y, VOULGARIS PV, PLIAKOU XI, PAPADOPOULOS CG, DROSOS AA: Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis 2005; 64: 940-2.
33. BRANDT J, LISTING J, HAIBEL H et al.: Longterm efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 2005; 44: 342-8.
34. CALIN A, DIJKMANS BAC, EMERY P et al.: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1594-600.
35. BRANDT J, KHARIOUZOV A, LISTING J et al.: Six-month results of a double-blind, placebo- controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667-75.
36. DAVIS JC JR, VAN DER HEIJDE D, BRAUN J et al.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. A randomised, controlled trial. Arthritis Rheum 2003; 48: 3230-6.
37. VAN DER HEIJDE D, KIVITZ A, SCHIFF MH Et Al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-46.
38. RUDWALEIT M, CLAUDEPIERRE R, WORDSWORTH P et al.: Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009; 36: 801-8.
39. ZOCHLING J, BRAUN J: Remission in ankylosing spondylitis. Clin Exp Rheumatol 2006; 24 (Suppl. 43): S88-92.
40. BRAUN J, SIEPER J: What is the most important outcome parameter in ankylosing spondylitis? Rheumatology 2008; 47: 1738-40.
41. BRANDT J, LISTING J, SIEPER J, RUDWALEIT M; VAN DER HEIJDE D, BRAUN J: Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1438-44.
42. VAN DER HEIJDE D, PANGAN AL, SCHIFF MH et al.: Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 2008; 67: 1218-21.
43. CHEUNG PP, TYMMS KE, WILSON BJ et al.: Infliximab in severe active ankylosing spondylitis with spinal ankylosis. Intern Med J 2008; 11. Published online first.
44. RUDWALEIT M, OLIVIERI I, BOKI KA et al.: Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion. Rheumatology 2009; 48: 551-7.
45. SCHNEEWEISS S, SETOGUCHI S, WEINBLATT ME et al.: Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 1754-64.
46. ZINK A, ASKLING J, DIXON WG, KLARESKOG L, SILMAN AJ, SYMMONS DP: European Biologics Registers- Methodology, selected results, and perspectives. Ann Rheum Dis 2008; Published online first.
47. ASKLING J, BAECKLUND E, GRANATH F et al.: Anti-tumor necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009; 68: 648-53.
48. ASKLING J, KLARESKOG L, BLOMQVIST P, FORED M, FELTELIUS N: Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006; 65: 1184-7.
49. BRAUN J, BARALIAKOS X, LISTING J et al.: Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor a agents. Arthritis Rheum 2007; 57: 639-47.
50. LIM LL, FRAUNFELDER FW, ROSENBAUM JT: Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007; 56: 3248-52.
51. BRAUN J, BARALIAKOS X, LISTING J, SIEPER J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52: 2447-51.
52. KIRCIK LH, DEL ROSSO JQ: Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol 2009; 8: 546-59.
53. KO JM, GOTTLIEB AB, KERBLESKI JF: Induction and exacerbation of psoriasis with TNFblockade therapy: J Dermatol Treat 2009; 20: 100-8.
54. DE VRIES MK, WOLBINK GJ, STAPEL SO et al.: Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis 2007; 66: 133-4.